Concerns and questions to raise at the 2023 AGM on Nov. 30th., page-30

First 30 Last

Share
Profile

Follow
Kevo88

3,107 Posts.

1177

20/10/23

13:04

Post #: 70448661
Share

Originally posted by Kevo88: ↑

Yeh there was a youtube video I watched a while ago.

It was about how new industries take off and then cowboys show up and jump on the bandwagon as such. This is true of the nickel craze way back when and now even the lithium craze. Are our management simply cowboys???

One has to ask themself. Not only do we have the asset, do we have competent management to get to where we are strategically aiming for.

While I am a strong supported of SYA, the macro is pretty grim atm and I imaging the comments of "reviewing our strategic direction" not only causes some more instability but it left many questioning if SYA management might try and change our direction. You know the one Brett really wanted.

He didnt see eye to eye on where he wanted to go with the rest of BoD and now here we are?

Im not going to make fun of JB or his size and I dont know him from a bar of soap with regards to his capabilities. All I know is what was listed on his skills page demonstrates he simply isnt qualified enough to get to where SYA current strategic direction is headed and that was always downstream after NAL purchase.

Why acquire an even 1/3 built out carb plant if you don't intend to use it.

Aside from this, I also noted something I spotted on simply wall street website the other day. It was showing SYA has no independent directors and lists this as a big risk to the company. The reason being is SYA cannot mitigate risk correctly when current directors are all arms length.

We have a great asset in NAL and an even better one in Moblan but current management simply isnt adequate for the future of SYA.

We have already seen what shareholders are capable of as we are a 50% majority vote in SYA. They need to be put on notice in regards to diversity and skill set and resign if they do not want to follow the vision Brett instilled into shareholders. We cannot change the direction of this ship when we have a plan already laid out and a place we need to be!

Expand

edit note: *non-arms length*

SYA Price at posting: 8.2¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 41 more messages in this thread...

First 30 Last

Add SYA (ASX) to my watchlist

(20min delay)
Last 3.5¢		Change 0.004(11.3%)		Mkt cap ! $355.1M

Open	High	Low	Value	Volume
3.3¢	3.6¢	3.2¢	$1.954M	57.65M

Buyers (Bids)

No.	Vol.	Price($)
42	5993225	3.4¢

Sellers (Offers)

Price($)	Vol.	No.
3.5¢	3766915	15

View Market Depth

No.	Vol.	Price($)
42	5993225	0.034
31	9728453	0.033
30	8350279	0.032
19	8714812	0.031
31	4361630	0.030

Price($)	Vol.	No.
0.035	3766915	15
0.036	14374111	58
0.037	10891800	35
0.038	12940190	29
0.039	4712758	20

Last trade - 14.32pm 07/10/2024 (20 minute delay)

SYA (ASX) Chart

Concerns and questions to raise at the 2023 AGM on Nov. 30th., page-30

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Concerns and questions to raise at the 2023 AGM on Nov. 30th., page-30

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News